Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Intermediate release (IR) Paliperidone
Intermediate release Paliperidone · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Intermediate release (IR) Paliperidone | DRUG | - |
Inclusion Criteria: * Patients with normal hepatic function:Normotensive at screening, with supine (5 minutes) blood pressure between the range of 95 to 160 mmHg systolic, inclusive, and 55 to 95 mmHg diastolic, inclusive, demographically comparable to the hepatic impairment group with respect to a...
Top 15 of 16 competitors
Intermediate release paliperidone is an investigational small molecule formulation of paliperidone developed by Johnson & Johnson for schizophrenia. It is also known as intermediate release (IR) paliperidone. The formulation has been studied in a Phase 1 pharmacokinetics trial, and no Phase 2 or later trials are recorded.
Intermediate release paliperidone is being studied for schizophrenia. A Phase 1 trial also enrolled volunteers with hepatic impairment to assess how liver function affects the drug. The program remains in early clinical development, and the formulation has not been approved for any indication.
Intermediate release paliperidone is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. Johnson & Johnson is the sponsor behind the clinical program for this formulation.
Intermediate release paliperidone is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed for this formulation.
Intermediate release paliperidone has been evaluated in one completed Phase 1 trial, NCT00791284, titled A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function. That trial enrolled 20 participants, including healthy volunteers, and examined schizophrenia and hepatic impairment. No active trials are listed.
Yes. Intermediate release paliperidone is also known as intermediate release (IR) paliperidone, so the two names refer to the same investigational formulation. Searches using either name point to the same Johnson & Johnson Phase 1 program in schizophrenia.